Stock Track | SpyGlass Pharma Soars 50% in Intraday Trading on Nasdaq Debut After $150 Million IPO

Stock Track

7小時前

SpyGlass Pharma, Inc. (SGP) saw its stock price soar 50.00% during intraday trading on Friday, marking a strong debut on the Nasdaq exchange.

The biopharmaceutical company recently completed a $150 million initial public offering, pricing 9.4 million shares at $16 each. Market indications suggested the stock would open significantly above its IPO price, reflecting strong investor interest in the company's innovative drug delivery systems for chronic eye diseases.

SpyGlass Pharma's lead program, the BIM-IOL system, integrates glaucoma treatment into standard cataract surgery, offering long-acting therapy options. The company's successful IPO and market debut highlight investor confidence in its technology and growth potential in the ophthalmology sector.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1152577895"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152577895\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152577895?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-07 01:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152577895","market":"us","top_or_hot":-1,"title":"Stock Track | SpyGlass Pharma Soars 50% in Intraday Trading on Nasdaq Debut After $150 Million IPO","media":"Stock Track","content":"<p>SpyGlass Pharma, Inc. (SGP) saw its stock price soar 50.00% during intraday trading on Friday, marking a strong debut on the Nasdaq exchange.</p><p>The biopharmaceutical company recently completed a $150 million initial public offering, pricing 9.4 million shares at $16 each. Market indications suggested the stock would open significantly above its IPO price, reflecting strong investor interest in the company's innovative drug delivery systems for chronic eye diseases.</p><p>SpyGlass Pharma's lead program, the BIM-IOL system, integrates glaucoma treatment into standard cataract surgery, offering long-acting therapy options. The company's successful IPO and market debut highlight investor confidence in its technology and growth potential in the ophthalmology sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | SpyGlass Pharma Soars 50% in Intraday Trading on Nasdaq Debut After $150 Million IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | SpyGlass Pharma Soars 50% in Intraday Trading on Nasdaq Debut After $150 Million IPO\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-02-07 01:29</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>SpyGlass Pharma, Inc. (SGP) saw its stock price soar 50.00% during intraday trading on Friday, marking a strong debut on the Nasdaq exchange.</p><p>The biopharmaceutical company recently completed a $150 million initial public offering, pricing 9.4 million shares at $16 each. Market indications suggested the stock would open significantly above its IPO price, reflecting strong investor interest in the company's innovative drug delivery systems for chronic eye diseases.</p><p>SpyGlass Pharma's lead program, the BIM-IOL system, integrates glaucoma treatment into standard cataract surgery, offering long-acting therapy options. The company's successful IPO and market debut highlight investor confidence in its technology and growth potential in the ophthalmology sector.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SGP","symbol_name":"SpyGlass Pharma Inc","start_time":0,"source_url":"","article_id":"1152577895","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152577895","pubTimestamp":1770398971,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"SpyGlass Pharma, Inc. (SGP) saw its stock price soar 50.00% during intraday trading on Friday, marking a strong debut on the Nasdaq exchange.The biopharmaceutical company recently completed a $150...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SGP":"SpyGlass Pharma Inc"},"translate_title":"个股追踪|Spyglass Pharma 1.5亿美元IPO后纳斯达克首秀盘中大涨50%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SGP":1},"content_text":"SpyGlass Pharma, Inc. (SGP) saw its stock price soar 50.00% during intraday trading on Friday, marking a strong debut on the Nasdaq exchange.The biopharmaceutical company recently completed a $150 million initial public offering, pricing 9.4 million shares at $16 each. Market indications suggested the stock would open significantly above its IPO price, reflecting strong investor interest in the company's innovative drug delivery systems for chronic eye diseases.SpyGlass Pharma's lead program, the BIM-IOL system, integrates glaucoma treatment into standard cataract surgery, offering long-acting therapy options. The company's successful IPO and market debut highlight investor confidence in its technology and growth potential in the ophthalmology sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}